Lumiracoxib in the management of osteoarthritis and acute pain

  title={Lumiracoxib in the management of osteoarthritis and acute pain},
  author={B. Bannwarth and F. Berenbaum},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1551 - 1564}
  • B. Bannwarth, F. Berenbaum
  • Published 2007
  • Medicine
  • Expert Opinion on Pharmacotherapy
  • Lumiracoxib is a highly selective COX-2 inhibitor with a novel chemical structure and a relatively short plasma half-life. It has been approved in > 40 countries for the symptomatic treatment of osteoarthritis and/or acute pain related to primary dysmenorrhoea and dental or orthopaedic surgery. In these conditions, lumiracoxib has proved to be as effective as standard doses of conventional NSAIDs and other COX-2 selective inhibitors (coxibs). According to the Therapeutic Arthritis Research… CONTINUE READING
    Ibuprofen: pharmacology, efficacy and safety
    • 257
    • PDF
    In Vitro Metabolic Activation of Lumiracoxib in Rat and Human Liver Preparations
    • 34
    • PDF
    The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice
    • 4
    Investigational pharmacology for low back pain
    • 6
    • PDF


    Publications referenced by this paper.
    Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
    • 13
    • Highly Influential
    Efficacy of Lumiracoxib in Osteoarthritis: A Review of Nine Studies
    • 28
    Acetaminophen or NSAIDs for the treatment of osteoarthritis.
    • 43
    Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
    • 45